3-Ethyl-4-Methyl-2-Oxo-N-[2-(4-Sulfamoylphenyl)Ethyl]-2,5-Dihydro-1H-Pyrrole-1-Carboxamide

In large-scale API manufacturing campaigns for sulfonylurea oral hypoglycemic agents, 3-ethyl-4-methyl-2-oxo-N-[2-(4-sulfamoylphenyl)ethyl]-2,5-dihydro-1H-pyrrole-1-carboxamide functions as the penultimate intermediate preceding the final sulfonyl isocyanate condensation step. The compound is isolated via a two-stage solvent swap and antisolvent crystallization from a dichloromethane–n-heptane system, which reduces residual 2-(4-sulfamoylphenyl)ethylamine below 0.15 area-% by HPLC when monitored at 210 nm with a C18, 5 μm, 250 × 4.6 mm column. Process robustness studies conducted in 5,000 L glass-lined reactors demonstrate that maintaining the amide coupling pH between 7.8 and 8.2 using triethylamine controls the formation of the symmetrical urea dimer to less than 0.10% w/w, a critical quality attribute referenced in multiple Type II drug master files. The wet cake is dried under vacuum at 45 ± 2 °C to a loss-on-drying endpoint of ≤0.5%, confirmed by Karl Fischer titration in pyridine-free reagent, while residual dichloromethane and heptane comply with USP <467> Option 1 limits. Manufacturers supplying this intermediate under ICH Q7 guidelines typically release material with purity ≥99.5% by area normalization, alongside a certificate of analysis that includes LC–MS molecular ion confirmation at m/z 380.1 [M+H]⁺ and X-ray powder diffraction verification of crystallinity against an in-house reference pattern.

Generic Drug Substance Manufacturing: Process Scale-Up and Continuous Flow Processing

When transitioning from batch-mode amide bond formation to a continuous flow platform for cost reduction, the intermediate’s rapid coupling kinetics under anhydrous conditions are exploited using a Corning® Advanced-Flow™ G1 reactor with a SiC plate module having a heart-shaped channel geometry that provides a heat-transfer coefficient exceeding 1,700 W m⁻² K⁻¹. A solution of 3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrole-1-carbonyl chloride in anhydrous THF at 0.45 mmol/mL and a separate stream of 2-(4-sulfamoylphenyl)ethylamine with triethylamine in THF–water 95:5 v/v are fed at a molar ratio of 1:1.03 and a total flow rate of 12 mL/min, achieving a residence time of 45 seconds at −5 °C. In-line FTIR monitoring at 1785 cm⁻¹ (carbonyl chloride C=O stretch disappearance) triggers an automated diversion valve that collects the reaction stream into a receiving vessel containing dilute aqueous NaHCO₃; conversion regularly exceeds 99.2% by offline UHPLC analysis. The subsequent continuous extraction and liquid–liquid separation in a Zaiput SEP-10 membrane separator permits toluene replacement of THF prior to crystallization, yielding material with a mean particle size D₅₀ of 42 μm after milling on a Jet-O-Mizer with nitrogen at 7 bar grinding pressure. This flow approach reduces the total processing time from 14 hours (batch) to 82 minutes (solution to dried solid) and eliminates the formation of a 0.3% des-ethyl impurity that is observed when batch reactors experience jacket temperature overshoot above 12 °C during the exothermic quench.

Published data for this specific configuration in continuous flow mode is limited to three CDMO pilot campaigns, but the general trend indicates that the removal of the sulfonamide protective group is not required if the final sulfonylurea formation is executed in a single telescoped process; the free –SO₂NH₂ group reacts selectively with an alkyl isocyanate in the presence of a catalytic quantity of 1,4-diazabicyclo[2.2.2]octane (DABCO) at 0.5 mol% loading, suppressing the competing N-acylurea side product to below the ICH Q3A reporting threshold. A significant operational boundary is that the intermediate must be stored at ≤−20 °C under argon if not immediately processed, as exposure to ambient humidity above 40% RH for more than 8 hours leads to hydrolytic ring-opening of the pyrrolinone, detected as a rise in a polar impurity with relative retention time 0.38 against the parent peak.

Hydrolytic Stability Under Forced Degradation Conditions: Analytical Benchmarking

Stressed stability studies performed per ICH Q1A(R2) on three representative pilot batches reveal that the carboxamide linkage remains intact under thermal stress at 60 °C/75% RH for 14 days, with a maximum degradation of 0.28% total impurities, whereas acid hydrolysis in 0.1 N HCl at 40 °C over 24 hours cleaves the pyrrolinone ring to yield 3-ethyl-4-methyl-3-pyrrolin-2-one and the sulfonamide amine fragment in near-stoichiometric proportion. The most sensitive degradation pathway is photolytic: exposure to a xenon lamp conforming to ICH Q1B Option 2 for an integrated near-UV energy of 200 Wh/m² and visible light of 1.2 million lux·hours produces a photo-dimer that absorbs at 320 nm and grows to 1.1% w/w, necessitating opaque packaging and amber glass vial storage for reference standard aliquots. Mass balance is consistently within 97–102%, as the dimer is chromatographically resolved on a phenyl-hexyl column with an acetonitrile–phosphate buffer (pH 3.0) gradient. These forced degradation profiles are used to define the peak purity threshold for the working standard used in compendial testing and are incorporated into the justification of specification limits in ANDA submissions referencing USP glimepiride monographs.

The following table compares the impurity profile between a standard batch synthesis route and the alternative continuous flow process to support the selection of quality control strategy in abbreviated new drug applications.

Quantification employs an external standard method with a calibration range from the limit of quantitation (0.03 μg/mL) to 150% of the specification level, and the relative response factors are validated per ICH Q2(R1) with a correlation coefficient r ≥ 0.999. Forced degradation peak purity is confirmed by diode array detection across 200–400 nm, and each identified impurity above the identification threshold is structurally characterized by high-resolution Q-TOF MS/MS.

The compound’s utility in pharmacopoeial reference standard preparation extends beyond single-analyte impurity profiling. Official USP and EP glimepiride monographs require a system suitability mixture containing structurally related compounds including the pyrrolinone carboxamide intermediate, making the availability of a highly characterized batch essential for retention time confirmation and relative response factor determination. A certified reference standard is typically supplied with a mass balance assignment by quantitative NMR using a maleic acid internal standard traceable to NIST SRM 350b, with an expanded uncertainty of 0.4% (k=2), and a certificate detailing water content by coulometric Karl Fischer, residual solvent panel by headspace GC–FID, and sulfated ash content. When used as a retention time marker in UHPLC–UV methods with a sub-2-μm column operating at 45 °C and a flow of 0.35 mL/min, the intermediate elutes between the two closest eluting known impurities of glimepiride, a separation critically influencing method ruggedness across different column lots. Laboratories performing bioequivalence studies also rely on this intermediate as an internal standard surrogate during method development for plasma drug concentration assays, where deuterated analogs are not yet commercially available; the sulfonamide moiety enables selective solid-phase extraction on a mixed-mode anionic sorbent prior to LC–MS/MS quantification with a lower limit of quantification of 0.5 ng/mL in human plasma.

Carbonic Anhydrase Inhibition and Targeted Library Synthesis

The 4-sulfamoylphenyl pharmacophore is a well-established zinc-binding group in human carbonic anhydrase (hCA) isoforms, and the N-(2-phenylethyl)carboxamide spacer attached to a substituted pyrrolinone ring places the compound within the chemical space of isoform-selective inhibitors explored for glaucoma, edema, and neuropathic pain. In high-throughput screening against hCA II and hCA XII using a stopped-flow CO₂ hydration assay adapted from Khalifah’s method, derivatives where the pyrrolinone 3-ethyl-4-methyl motif is retained exhibit Kᵢ values in the low nanomolar range, with the free sulfonamide nitrogen directing a conserved water network in the active site as confirmed by X-ray crystallography at 1.7 Å resolution. Medicinal chemistry groups use this intermediate as a scaffold-diversification point: the carboxamide nitrogen can be alkylated under Mitsunobu conditions to introduce a tertiary amide, or the pyrrolinone double bond can be selectively hydrogenated over 10% Pd/C at 30 psi H₂ to give a saturated γ-lactam analogue with altered conformational flexibility. Parallel library synthesis in 96-well format on a ChemSpeed platform typically starts from a common stock solution of the intermediate in DMSO at 100 mM, and the first-generation array focuses on varying the acylating agent at the sulfonamide nitrogen while monitoring aqueous solubility by nephelometry at 620 nm to flag poorly soluble candidates. A critical incompatibility arises when coupling with isocyanates derived from secondary amines: traces of moisture promote competing formation of the symmetric urea, which precipitates in the reaction well and leads to false-negative inhibition results unless the well contents are filtered through a 0.2 μm PTFE membrane before the enzyme assay.

In vivo efficacy models for topical ocular delivery require the synthesis of citrate or phosphate salts to improve aqueous solubility for corneal penetration; the sulfamoyl group is sufficiently acidic (pKₐ of the –SO₂NH– proton estimated at 9.3 by potentiometric titration in a mixed organic–aqueous medium) to enable salt formation with alkali metal hydroxides, though these salts are hygroscopic and must be handled in a glove box with <2% RH for solid-state characterization. Thermogravimetric analysis coupled with FTIR evolved-gas analysis reveals that the non-salt form undergoes a single sharp melting endotherm at 173.5 °C (onset, DSC, 5 K/min), while the sodium salt exhibits a gradual dehydration loss between 40 °C and 120 °C corresponding to 3.5 water molecules per formula unit. Pharmacokinetic profiling in New Zealand White rabbits with microdialysis sampling of the aqueous humour demonstrates that the parent intermediate, when formulated as a 0.1% w/v suspension in hydroxypropyl-β-cyclodextrin buffered to pH 7.4, achieves an intraocular concentration above the hCA II IC₅₀ for 6 hours, making it a viable formulation prototyping tool despite its intended fate as a synthetic intermediate rather than a drug product itself.

In production settings, the particle size distribution of the intermediate directly influences the dissolution rate in the buffer system used for eye-drop formulation screening. Jet-milled material with a D₉₀ of 15 μm dispersed in 0.05 M phosphate buffer containing 0.02% w/v polysorbate 80 generates a dissolution profile at 37 °C with a T₈₀ of 12 minutes, whereas unmilled lots with a D₉₀ exceeding 80 μm require more than 60 minutes to reach the same extent, a rate difference that confounds timed enzyme inhibition pre-incubation protocols unless standardized.

A parallel application that has emerged from preclinical toxicology investigations is the use of the free sulfonamide as a building block for photoaffinity labels targeting the sulfonylurea receptor (SUR1) of the pancreatic β-cell ATP-sensitive potassium channel. The pyrrolinone carboxamide is functionalized with a trifluoromethyl diazirine photoreactive group via sulfonamide N-alkylation, followed by a click-chemistry conjugation of biotin-PEG₃-azide to enable streptavidin pull-down assays. The synthesis is carried out under amber light illumination, and the final photoprobe is stored at −80 °C in degassed ethanol to prevent diazirine decomposition. Validation of the probe’s photoinsertion efficiency is performed by UV irradiation at 365 nm for 10 minutes in the presence of recombinant SUR1 membrane preparations, with western blot detection relying on the biotin tag; signal-to-noise ratios of >8 are routinely achieved at probe concentrations of 500 nM. This high-value application consumes only milligram quantities of the intermediate per study but requires exhaustive documentation of the batch’s heavy metal content (in compliance with ICH Q3D) to avoid interference with electrophysiological recordings from patch-clamped β-cells.